Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Conclusion: UST showed to be effective and persistent, inducing short-term clinical benefit and endoscopic response in this real-life nationwide study of CD patients. Significant corticosteroid tapering in patients with highly treatment refractory and long-standing CD was observed.
PMID: 31184512 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
More News: Corticosteroid Therapy | Crohn's Disease | Finland Health | Gastroenterology | Inflammatory Bowel Disease | PET Scan | Stelara | Study